绿康生化(002868) - 2022 Q4 - 年度财报

Financial Performance - The company reported a plan not to distribute cash dividends, issue bonus shares, or increase capital from reserves[6]. - The company's operating revenue for 2022 was ¥329,850,238.49, a decrease of 9.23% compared to ¥363,386,382.24 in 2021[28]. - The net profit attributable to shareholders for 2022 was -¥121,938,109.79, representing a decline of 368.20% from -¥26,043,911.65 in 2021[28]. - The net cash flow from operating activities was -¥8,833,005.89 in 2022, a decrease of 125.11% compared to ¥35,170,418.50 in 2021[28]. - The total assets at the end of 2022 were ¥1,239,862,406.54, down 1.47% from ¥1,258,398,896.70 at the end of 2021[28]. - The basic earnings per share for 2022 was -¥0.79, a decrease of 364.71% from -¥0.17 in 2021[28]. - The weighted average return on net assets was -18.57% in 2022, down 15.04% from -3.53% in 2021[28]. - The company reported a significant increase in non-recurring losses, with a net profit after deducting non-recurring gains and losses of -¥123,209,841.64 in 2022, compared to -¥11,367,490.76 in 2021, a decline of 983.88%[28]. - The company reported a total profit of -CNY 134,110,321.30 and a net profit attributable to shareholders of -CNY 121,938,109.79, primarily due to high costs from new projects and market downturns[65]. Market and Industry Trends - The company is focused on expanding its market presence and developing new products and technologies, although specific figures are not provided in the available content[5]. - The veterinary medicine industry in China has seen a significant increase in production standards since the implementation of GMP regulations, leading to improved product quality and a favorable development environment for veterinary companies[42]. - In 2022, the top 20 pig farming companies accounted for 20%-25% of the total pig output and breeding stock, indicating a trend towards industry consolidation[44]. - The total pig output in China for 2022 was 699.95 million heads, representing a growth of 4.3% compared to the previous year[44]. - The global photovoltaic (PV) installed capacity reached 392.04 GW by the end of 2022, with a new installed capacity of 87.4 GW in China for the same year[46]. - The global demand for encapsulation films in the photovoltaic sector increased by 50% in 2022, reaching 2.7 billion square meters[48]. - The forecast for new PV installations in China for 2023 is between 95-120 GW, with global installations expected to reach 280-330 GW[46]. Strategic Initiatives - The company plans to acquire 100% equity of Jiangxi Weike New Materials Technology Co., Ltd., entering the photovoltaic film industry[41]. - The company plans to acquire 100% equity of Jiangxi Weike for cash, expanding into the photovoltaic film industry[68]. - The company is actively pursuing a dual-main business model of "animal protection products + photovoltaic film products" to ensure sustainable development[68]. - The company is focusing on developing green and safe veterinary drugs to meet future market demands[66]. - The company is currently developing new products, including L-tryptophan production technology, to enhance market competitiveness and increase sales[91]. - The company plans to invest a total of 6 billion RMB in the photovoltaic film project, which will add 100 production lines upon completion[114]. - The first phase of the project will complete 40 production lines within two years, with expected annual sales of 4 billion RMB upon reaching full capacity[115]. Governance and Compliance - The company has established a comprehensive governance structure and internal control system, ensuring compliance with relevant laws and regulations, and has conducted multiple shareholder meetings to uphold shareholder rights[127]. - The company has implemented a strict remuneration decision-making process based on its articles of association and relevant rules[152]. - The company has maintained effective internal control over financial reporting as of December 31, 2022, according to the internal control audit report[176]. - The company has established a commitment to not reduce its shareholding in the acquired shares through centralized bidding within 12 months of the transfer[194]. - The company has ensured compliance with all regulatory requirements regarding related party transactions[195]. Environmental and Social Responsibility - The company is subject to various environmental protection laws and has obtained necessary environmental permits for its operations[179]. - The company invested a total of 123.15 million yuan in environmental protection, including greening, pollution control, and environmental taxes in 2022[187]. - The company provided 40,000 yuan in support for poverty alleviation and rural revitalization efforts in 2022, specifically targeting impoverished villages[191]. - The company has engaged third-party operations for online monitoring of emissions and wastewater treatment to ensure compliance with environmental regulations[185]. - The company has committed to clean production practices and water conservation measures across all departments and workshops[187]. Research and Development - The company has accumulated significant technical reserves and customer resources, positioning itself as a major manufacturer of similar products globally, while actively exploring domestic and international markets[56]. - The company has obtained a total of 19 invention patents and 15 utility model patents, demonstrating its strong commitment to innovation and technology advancement in the production of veterinary drugs[59]. - The company's R&D investment decreased by 12.07% to ¥21,824,916.67 in 2022, accounting for 6.62% of operating revenue[92]. - The number of R&D personnel increased by 4.88% to 86 in 2022, with a slight decrease in the proportion of R&D staff to total employees from 11.19% to 10.91%[91]. Employee and Management Changes - The company experienced significant management changes, with multiple executives resigning for personal reasons, including the vice general managers and a board member[137]. - The current chairman and general manager is Mr. Lai Tanping, who has been in leadership roles since December 2009[139]. - The company has a total of 14 directors and supervisors, with varying remuneration amounts[153]. - The total number of employees at the end of the reporting period was 788, with 644 in the parent company and 144 in major subsidiaries[162].